Intermittent androgen deprivation therapy with gonadotropin-releasing-hormone (GnRH) agonists can prevent or delay disease progression and development of castration resistant prostate cancer for subpopulations of prostate cancer patients. It may also reduce risk and severity of side effects associated with chemical castration in prostate cancer (PCa) patients. One of the earliest comprehensively documented clinical trials on this was reported in a Canadian patient population treated with leuprorelin preceded by a lead-in with cyproterone acetate. A systems-based mixed effect analysis of testosterone response in active and recovery phases allows inference of new information from this patient population. Efficacy of androgen deprivation therapy is presumed to depend on a treshold value for testosterone at the nadir, below which no additional beneficial effects on PSA reponse can be expected, and occurance of testosterone breakthroughs during active therapy. The present analysis results in a mixed effect model, incorporating GnRH receptor activation, testosterone turnover and feedback mechanisms, describing and predicting testosterone inhibition under intermittent androgen deprivation therapy on the individual and population level, during multiple years of therapy. Testosterone levels in these patients decline over time with an estimated first order rate constant of 0.083 year−1(T1/2 = 8.4 y), with a substantial distribution among this patient population, compared to the general population. PCa patients leaving the trial due to unmanageble PSA relapse appear to have slightly higher testosterone levels at the nadir than sustained responders. These findings are expected to contribute to an increased understanding of the role of testosterone in long term disease progression of prostate cancer.
This is a preview of subscription content, access via your institution.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Morote J, Planas J, Salvador C et al (2009) Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 103:332–335. https://doi.org/10.1111/j.1464-410X.2008.08062.x
Oefelein MG, Resnick MI (2003) Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62:207–213. https://doi.org/10.1016/S0090-4295(03)00331-5
Spitz A, Young JM, Larsen L et al (2012) Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis 15:93–99. https://doi.org/10.1038/pcan.2011.50
Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642. https://doi.org/10.1016/j.eururo.2016.08.002
Pickles T, Hamm J, Morris WJ et al (2012) Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int 110:E500–E507. https://doi.org/10.1111/j.1464-410X.2012.11190.x
Crawford ED, Moul JW, Sartor O, Shore ND (2015) Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Toxicol. https://doi.org/10.1517/174252551073711
Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456. https://doi.org/10.1200/JCO.2006.06.2497
Shaw GL, Wilson P, Cuzick J et al (2007) International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99:1056–1065. https://doi.org/10.1111/j.1464-410X.2007.06770.x
Klotz L, Toren P (2012) Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol 19:13–21. https://doi.org/10.3747/co.19.1298
Hussain M, Tangen C, Higano C et al (2016) Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J Clin Oncol 34:280–285. https://doi.org/10.1200/JCO.2015.62.8065
Romero E, Velez De Mendizabal N, Cendrós JM et al (2012) Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharmacol Exp Ther 342:788–798. https://doi.org/10.1124/jpet.112.195560
Snelder N, Drenth HJ, Riber Bergmann K et al (2019) Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin. Br J Clin Pharmacol 85:1247–1259. https://doi.org/10.1111/bcp.13891
Gries JM, Munafo A, Porchet HC, Verotta D (1999) Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. J Pharmacol Exp Ther 289:371–377
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45. https://doi.org/10.1038/35094009
Klotz L, O’Callaghan C, Ding K et al (2015) Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 33:1151–1156. https://doi.org/10.1200/JCO.2014.58.2973
Bruchovsky N, Klotz L, Crook J et al (2006) Final results of the canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107:389–395. https://doi.org/10.1002/cncr.21989
Bruchovsky N, Klotz L, Crook J, Goldenberg SL (2007) Locally advanced prostate cancer - biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109:858–867. https://doi.org/10.1002/cncr.22464
Jacqmin P, Snoeck E, Van Schaick EA et al (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 34:57–85. https://doi.org/10.1007/s10928-006-9035-z
Bruchovsky N (2013) dataTanaka.zip. http://nicholasbruchovsky.com/dataTanaka.zip. Accessed 16 May 2018
Thompson IM (2001) Flare associated with LHRH-agonist therapy. Rev Urol 3(Suppl 3):S10–S14
Tod M (2008) Evaluation of drugs in pediatrics using K-PD models: perspectives. Fundam Clin Pharmacol 22:589–594. https://doi.org/10.1111/j.1472-8206.2008.00649.x
Beal S, Sheiner LB, Boeckmann A, Bauer RJ 2009 NONMEM user’s guides (1989-2009) Ellicott City, MD, USA
R Core Team 2013 R: a language and environment for statistical computing. Vienna, Austria. Available from http://www.R-project.org/. Accessed 30 Oct 2019
RStudio Team 2015 RStudio: integrated development environment for R. Boston, MA Available from http://www.rstudio.com/. Accessed 30 Oct 2019
Lindbom L, JEN Pihlgren P (2005) PsN-toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241–257. https://doi.org/10.1016/j.cmpb.2005.04.005
Gibiansky L, Gibiansky E, Bauer R (2012) Comparison of nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J Pharmacokinet Pharmacodyn 39:17–35. https://doi.org/10.1007/s10928-011-9228-y
Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation. Springer Available from https://www.springer.com/gp/book/9781441994844. Accessed 6 Jan 2016
Petersson KJF, Hanze E, Savic RM, Karlsson MO (2009) Semiparametric distributions with estimated shape parameters. Pharm Res 26:2174–2185. https://doi.org/10.1007/s11095-009-9931-1
Nguyen THT, Mouksassi MS, Holford N et al (2017) Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometrics Syst Pharmacol 6:87–109. https://doi.org/10.1002/psp4.12161
Kapoor A, Wu C, Shayegan B, Rybak AP (2016) Contemporary agents in the management of metastatic castration-resistant prostate cancer. J Can Urol Assoc 10:E414–E423. https://doi.org/10.5489/cuaj.4112
Xu X, Chen X, Hu H et al (2015) Current opinion on the role of testosterone in the development of prostate caer: a dynamic model. BMC Cancer 15:1–8. https://doi.org/10.1186/s12885-015-1833-5
Yamaguchi K, Izaki H, Takahashi M et al (2014) Changes in levels of prostate-specific antigen and testosterone following discontinuation of long-term hormone therapy for non-metastatic prostate cancer. J Med Investig 61:35–40. https://doi.org/10.2152/jmi.61.35
Kuo KF, Hunter-Merrill R, Gulati R et al (2015) Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer 13:10–16. https://doi.org/10.1016/j.clgc.2014.08.003
Crawford ED, Heidenreich A, Lawrentschuk N et al (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22:24–38. https://doi.org/10.1038/s41391-018-0079-0
Klotz L, Breau RH, Collins LL et al (2017) Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. J Can Urol Assoc 11:16–23. https://doi.org/10.5489/cuaj.4303
Klotz L, Shayegan B, Guillemette C et al (2018) Testosterone suppression in the treatment of recurrent or metastatic prostate cancer — a canadian consensus statement. J Can Urol Assoc 12:30–37. https://doi.org/10.5489/cuaj.5116
Cabarkapa S, Perera M, Sikaris K et al (2018) Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink? Prostate Int 6:1–6. https://doi.org/10.1016/j.prnil.2017.05.003
Rouleau M, Lemire F, Déry M et al (2019) Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocr Connect 8:132–140. https://doi.org/10.1530/EC-18-0476
Ferraldeschi R, Sharifi N, Auchus RJ, Attard G (2013) Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 19:3353–3359. https://doi.org/10.1158/1078-0432.CCR-12-0931
González-Sales M, Barrière O, Tremblay PO et al (2016) Modeling testosterone circadian rhythm in hypogonadal males: effect of age and circannual variations. AAPS J 18:217–227. https://doi.org/10.1208/s12248-015-9841-6
Conflict of interest
Nelleke Snelder, Maurice Ahsman and Joost DeJongh were paid consultants for Takeda Development Centre Europe Ltd. before the conduct of the analysis.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
DeJongh, J., Ahsman, M. & Snelder, N. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy. J Pharmacokinet Pharmacodyn (2021). https://doi.org/10.1007/s10928-020-09736-7
- Testosterone decline rate
- Population K-PD model
- Prostate cancer